pharma · Colorectal Cancer · Esophageal Varices in NASH Cirrhosis · GALT
Galectin Therapeutics
GALECTIN THERAPEUTICS INC
Galectin Therapeutics is a pharma organization headquartered in Norcross, USA. It trades on NYSE under ticker GALT. Primary therapeutic focus areas include Colorectal Cancer, Esophageal Varices in NASH Cirrhosis, Metasta
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US HQ
2000 Founded
36 Employees
Public company Type
GALT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US
- Founded
- 2000
- Employees
- 36
- Programs
- 12
- Drugs
- 5
- Patents
- 20
GR-MD-02
Phase 1 · small molecule · Non-Alcoholic Steatohepatitis (NASH)
GR-MD-02 for Non-Alcoholic Steatohepatitis (NASH) is a Phase 1 program (small_molecule) at GALECTIN THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Internal code GT-020
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- GALECTIN THERAPEUTICS INC
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Non-Alcoholic Steatohepatitis (NASH)
- Status
- completed
- Trials
- 1